Beta-Secretase (BACE) Inhibitors Pipeline to Witness Huge R&D Investment in the Coming Years

The study analysed that the Beta Secretase inhibitors pipeline comprised 15 drug candidates, in different stages of development.

As per the findings of the research, most of the pipeline drug candidates of BACE inhibitors are being developed to be administered by oral route.

Download Sample of This Research Report:

Among BACE inhibitors, AZD3293, a drug candidate of AstraZeneca plc and Eli Lilly and Company, received Fast Track designation by the U.S. Food and Drug Administration (FDA) in August 2016. The FDA’s Fast Track program was designed to expedite the development and review new therapies to treat serious conditions and tackle unmet medical needs.

Make Enquiry Before Buying the Report:

The research finds that different companies collaborated for the development of BACE inhibitors. Novartis entered in a global collaboration with Amgen to commercialize and develop BACE inhibitor program in September 2015 for Alzheimer’s disease.

Some of the key players developing BACE inhibitors are AstraZeneca plc, Eli Lilly & Company, Johnson & Johnson, and others.

BACE Inhibitors Pipeline Analysis

  • By Route of Administration
  • By Phase
  • By Company



Mr. Kundan Kumar

Manager – Client Partner

347, 5th Ave. #1402

New York City, NY – 10016

Toll-free: +18887787886 (USA/Canada)



Connect with us: LinkedIn | Twitter | Google + | Facebook

Designed by
Powered by
%d bloggers like this: